AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03883893 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will given if randomized to this group.
Study NCT03643887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMT Capsule DE
Description: 30 capsule one-time oral dose
Study NCT06701617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: restorative visual rehabitation
Description: black-and-white checkerboard patterns, visual stimulation program, restorative visual rehabitation
Study NCT06713304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A community-based Protective Behavioral Strategies program
Description: A 5-week group program delivered in a healthcare setting to teach and practice protective behavioral strategies. The objectives of each session are:~Session 1: Setting Safe Drinking Limit: The participants can identify the risk related to their drinking behavior, calculate a standard drink, and set a safe drinking limit.~Session 2: Choosing Nonalcoholic Drinks: The participants can understand the benefits of using nonalcoholic beverages and identify and select nonalcoholic beverages.~Session 3: Planning Ahead: The participants can make a plan to stop using during drinking events and know how to say no to alcohol use.~Session 4: Slowing down drinking: The participants can understand the benefits of slowing down drinking and know how to slow down their drinks.~Session 5: Avoid Risky Drinking Situations: The participants can understand the negative effects of excessive drinking and know how to avoid excessive drinking.
Study NCT05482516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway,
Study NCT05482516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a tumor-starving (anti-angiogenic) therapy. Avastin is designed to block a protein called vascular endothelial growth factor, or VEGF.
Study NCT06730074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with Parkinson's disease (PD)
Description: This is the first socially assistive robotic platform developed specifically for people with PD. If successful, this platform could be incorporated into the clinical toolbox at Adi Negev and other centres.
Study NCT03643887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 30 capsule one-time oral dose
Study NCT05363917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrunix with MTX placebo (+folate)
Description: True Human IgG4 monoclonal antibody that neutralizes Interleukin-1α
Study NCT05363917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natrunix placebo with MTX (+folate)
Description: Natrunix placebo with MTX (+folate)
Study NCT05029622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate
Description: Triptorelin 6-month formulation for IM on day 1 and Month 6.
Study NCT05465135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin
Description: Dihydroartemisinin 40mg three times a day for 12 consecutive weeks.
Study NCT05690321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opium tincture
Description: Self-administration of opium tincture (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
Study NCT06789172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Fasting before first dose of OKN4395
Study NCT06789172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fed
Description: Food provided to patient before first OKN4395 dose
Study NCT06203340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilizasyon and lumbal back school
Description: Lumbal back schooL
Study NCT06789549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine nasal drops
Description: Patients in experimental arms received 1 mL of 0.1% epinephrine nasal drops before nasotracheal intubation
Study NCT06789549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxymetazoline nasal drops
Description: Patients in experimental arms received 1 mL of 0.1% oxymetazoline nasal drops before nasotracheal intubation
Study NCT06780332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDD to Palynziq
Description: Delivery of gradually increasing doses of Palynziq at fixed time intervals over the course of several hours to a cumulative dose equal to the reactive dose. Reactive dose is defined as the dose at which the reactive HSR occurred which led to treatment interruption or reduction of dose or dose frequency.
Study NCT04663997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: IA of 7.4GBq (± 10%) IV every 6 weeks; maximum 6 cycles
Study NCT04663997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2 IV every 3 weeks maximum 12 cycles
Study NCT06789952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: MBSR is a psychological therapeutic intervention that emphasizes the focused, non-judgmental awareness of present-moment experiences without efforts being made to alter or avoid them. It is a practice that is embedded in mind/body and integrative medicine, it combines formal and informal practices of mindfulness.~The formal practices include body scanning, gentle hatha yoga - movements, sitting meditation and walking, meditation. Informal practices include mindfulness of daily activities, such as eating, driving, washing dishes, showering, etc. A variety of other exercises will be used as a support for developing proficiency in the practice of mindfulness. This class places strong emphasis on experiential learning. Each session will include:~* guided instruction while engaging in practices of mindfulness~* opportunity to reflect on experiences and ask questions~* discussion of topics related to the practice of mindfulness as a strategy for reducing stress
Study NCT06789952 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: The lifestyle sessions will include the following topics:~Movement -passive stretches and dynamic stretches, cardio HIIT exercise, flexibility and strength, and core and balance.~Nutrition Body - Include healthy eating with whole, clean, and nutritionally balanced meals; menu planning/prepping, snacking and noticing cravings and feelings of fullness or satiety.~Sleep - Include routine for evening, and morning for optimal sleep, logging routines and quality of sleep, tools to aid in falling asleep, and returning to sleep during the night, eating and sleep patterns Nature/Culture/Arts (with Kemper Museum of Contemporary Art - which will also take place during ½ day retreat) includes spending time in nature and journal experiences, reconnecting with the sun, and surround self with nature.~Financial - Focus on financial wellbeing, budgets/adjustments to budgets, and buying/spending patterns.~Cooking - Include healthy foods, smoothies, juices, kitchen appliances.
Study NCT06631937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Milk Oligosaccharides
Description: Human Milk Oligosaccharides provided in a commercially available infant formula powder, fed daily ad libitum from enrollement to 6 months of age
Study NCT05690321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administration of placebo (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
Study NCT06631937 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identical commercially available infant formula powder without Human Milk Oligosaccharides, fed daily ad libitum from enrollement to 6 months of age
Study NCT04736173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domvanalimab
Description: Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
Study NCT05383703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of MNC-168 enteric-coated capsules as a single oral drug
Description: Treatment of live bacterium MNC-168 as a single oral agent as a single oral drug in subjects with advanced malignant solid tumors. First, live fungi can directly or indirectly inhibit tumor growth or induce tumor cell apoptosis through their metabolites or surface proteins, and can also regulate the immune system, especially the tumor microenvironment, to play an antitumor function. Second, tumor immunotherapies exhibit different response levels in different populations, and live bacterial analogs derived from gut microbes may enhance the response to immunotherapy in weakly responding patients.
Study NCT05399355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Pulsed Shortwave Treatment with BioElectronics Model 088
Description: Application of 7-30 days of nonthermal, pulsed shortwave (radiofrequency) therapy with BioElectronics Model 088
Study NCT05399355 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Application of 7-30 days of a nonfunctional sham device(s)
Study NCT04736173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
Study NCT04736173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Study NCT04736173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Study NCT04736173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
Study NCT04736173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
Study NCT04736173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
Study NCT04736173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor
Study NCT06392997 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sample
Description: Saliva sample
Study NCT06130436 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-Remote Ischemic Conditioning
Description: Sham-Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg.
Study NCT06130436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning Once Daily
Description: Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, the morning of the postoperative day 1, the morning of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.~Sham-Remote Ischemic Conditioning (at the time points of 30 min after surgery, the afternoon of the postoperative day 1, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg.
Study NCT05814367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blink® Tears eye drops in a multidose bottle
Description: Control
Study NCT06130436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning Twice Daily
Description: Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.
Study NCT05221021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal estrogen
Description: 0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
Study NCT05221021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 50 MG [Myrbetriq]
Description: 50mg oral Mirabegron once daily
Study NCT06559358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: A two-channel portable electrical stimulation unit (BTL-4620, Czech Republic).
Study NCT05442632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: The patients received Hetrombopag 5mg orally d1-14 days, surgery will be conducted at d6-14 day
Study NCT05442632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patients received Placebo 5mg orally d1-14 days, surgery will be conducted at d6-14 day
Study NCT05298839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of core muscle endurance, hand grip strength, upper extremity functional performance, reaction time, agility performance and 3 minutes step test
Description: Core muscle endurance was evaluated with extensor muscle endurance test, flexor muscle endurance test and lateral muscle endurance test.~Hand Grip Strength was evaluated with Jamar hand dynamometer. Upper extremity functional performance was evaluated with health ball throwing test.~Reaction time was evaluated with Fitlight Trainer. Agility performance was evaluated with Pro-agility test. Cardiovascular endurance was evaluated with the 3-minute step test.
Study NCT06559358 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: electrical stimulation
Description: A two-channel portable electrical stimulation unit (BTL-4620, Czech Republic).
Study NCT05943665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: medication and therapy combined
Study NCT05650775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concerta
Description: 3-week trial of oral methylphenidate extended release
Study NCT05650775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adderall-XR
Description: 3-week trial of oral mixed amphetamine salts, extended release, administered only to children who do not show at least 30% improvement during the Concerta/Methylphenidate trial.
Study NCT06044090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants will take 2 pills of 100 mg totaling a 200 mg dose of minocycline per day.
Study NCT05814367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free investigational lubricating eye drops in a Novelia® eyedropper
Description: Test
Study NCT05157425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food Supplement
Description: Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination
Study NCT05157425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination
Study NCT04705467 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gynecological brachytherapy
Description: Management of gynecological malignancies is done through brachytherapy treatment, which involves the delivery of radiation via radioactive sources that are placed into or in close proximity to the tumour.
Study NCT06276387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Program
Description: Participants will receive eight weekly 2.5-hour group sessions and one day-long silent retreat, delivered online. Intervention content will include the MBSR program, which has been extensively studied with many different chronic conditions, and augmentations for individuals with rheumatic diseases. Each MBSR session will include meditation practices (e.g., sitting meditation, body scan, gentle hatha yoga, walking meditation, mindfulness of daily activities, awareness of pleasant and unpleasant events) and review of home practice. Participants will complete daily home practices for about 45 minutes per day and log their practice.
Study NCT06044090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 2 placebo tablets matching the Minocycline tablets daily for 5 days.
Study NCT05851391 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Burst Suppression EEG Target Intravenous Anesthesia
Description: The objective of the burst suppression EEG target is to stop seizures by titrating the anesthetic infusion to suppress most of the EEG background (>50% suppressed/attenuated). After this 24-hour period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
Study NCT05851391 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Seizure Suppression EEG Target Intravenous Anesthesia
Description: is to stop seizures by titrating the anesthetic infusion without suppressing most of the EEG background. This target would be continued for 24 hours. After this 24-hours period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
Study NCT05080322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Nasal 50 Mcg/Inh Nasal Spray, Azelastine Nasal 140 Mcg/Inh Nasal Spray
Description: on-demand INS (Fluticasone) combined with nasal spray AH1(Azelastine)
Study NCT04147949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: Oral capsules taken twice daily for 14 days
Study NCT04147949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules taken twice a day for 14 days
Study NCT05926583 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV5-hRKp.RPGR
Description: AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.
Study NCT05844384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nanodropper
Description: Nanodropper delivers 1/5 of eye drop volume compared to regular droppers
Study NCT05844384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular dropper
Description: Delivers full eye drop volume
Study NCT05182164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association of pembrolizumab + cabozantinib
Description: A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis.
Study NCT04767425 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: • 3D image-based cervical cancer brachytherapy will be delivered as 4 sessions x 7 Gy High Dose Rate (HDR) brachytherapy
Study NCT04722718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin
Description: Sintilimab:200mg,ivgtt,d1,21days/cycle;Apatinib:250mg po,d1-14days,21days/cycle;Albumin-Bound Paclitaxel(Nab-Paclitaxel):125mg/m2,ivgtt,d1,d8,21days/cycle;Carboplatin:AUC=1.5,ivgtt,d1,d8, 21days/cycle.Monitoring of blood routine, biochemical and urine routine, electrocardiogram, and record the patient's drug-related adverse reactions every cycle,according to the curative effect of patients, compliance and tolerance, neoadjuvant therapy 6 cycles,every 2 cycles to evaluate curative effect (ultrasonic, breast X-ray CT, bone scan, brain, lungs, assessment and breast MRI imaging).
Study NCT04758793 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: 3 citrated tubes and 3 EDTA tubes
Study NCT04758793 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: biopsy of abdominal paroie
Description: a muscle biopsy will be performed on the incision area
Study NCT05080322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Nasal 50 Mcg/Inh Nasal Spray
Description: on-demand or maintenance
Study NCT05080322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Nasal 50 Mcg/Inh Nasal Spray
Description: on-demand or maintenance
Study NCT04076735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal femoral replacement
Description: The distal portion of the femur (up to two thirds) is excised and replaced by a endoprosthesis incorporating a hinged total knee replacement.
Study NCT04076735 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Fixation (ORIF)
Description: A trained orthopaedic surgeon uses open or minimally invasive reduction techniques and achieves stable fixation with internal fixation devices (plates/screws or intramedullary nail) to restore structural integrity and alignment of the distal femur